Article Text

Download PDFPDF

379 Real world retrospective study of patients with epithelial ovarian cancer: an international comparison
  1. Sue Cheeseman1,
  2. Bethany Levick2,
  3. Eunji Nam3,
  4. Subin Lim3,
  5. Roman Rouzier4,
  6. Claire Bonneau4,
  7. Milan Paul Kubelac5,
  8. Patriciu A Achimas-Cadariu6,
  9. Jean Marc Classe7,
  10. Francois Bocquet7,
  11. Sven Becker8,
  12. Mariana Guergova-Kuras2 and
  13. Geoff Hall1
  1. 1Leeds Cancer Centre; Leeds Teaching Hospitals NHS Trust
  2. 2Iqvia
  3. 3Yonsei Severance
  4. 4Institut Curie
  5. 5The Oncology Institute ‘Prof Dr Ion Chiricuta’
  6. 6Ion Chiricuta Institute of Oncology
  7. 7Institut de Cancerologie Ouest
  8. 8Universitätsklinikum Frankfurt; Klinik für Gynäkologie und Geburtshilfe


Introduction/Background Clinical trials in Epithelial Ovarian Cancer (EOC) frequently examine treatment at a particular phase of the patient’s disease trajectory. Few major studies have examined the management of patients from diagnosis to death. This international network was developed to compare treatment sequencing and outcomes from six centres across Europe and South Korea.

Methodology This retrospective cohort study used longitudinal data collected from electronic medical records from 6 European and South Korean treatment centres. A standard protocol & common data model was developed to capture consistent data for patients diagnosed between January 2012 and December 2018, with a minimum of 12 months follow-up. Full treatment data was collected and categorized in programmes of care based on exemplar patient narratives. An extensive data harmonization process was implemented to ensure different country and site medical records were interpreted in a common manner. Overall survival (OS) and time to next treatment (TTNT) were estimated using Kaplan Meier methodology and outcomes stratified by categories of interest. Each site analysed their own EMR data and shared aggregated results for comparison.

Results Table 1 demonstrates patient characteristics from six sites. In total the overall study cohort includes 2889 patients. Median age for each centre ranged from 53 to 67 years. The majority of patients were FIGO stage III (range 31% to 66%) and high-grade serous morphology (52% to 69.9%) Additional data on treatment pathways and outcomes for each centre will be presented.

Abstract 379 Table 1

Characteristics of ovarian cancer patients treated at 6 participating centres between 2012 and 2018

Conclusion Preliminary analysis from this network suggests a consistent profile of adults treated for EOC across most contributing treatment centres in Europe, but with some substantial differences compared to patients treated at centres in South Korea and Romania. The establishment of a common data model between sites across five different countries allows for detailed exploration of the factors influencing differences in patient management and treatment outcomes in ovarian cancer patients.

Disclosures Sue Cheeseman: I receive consultancy fees from IQVIA

Bethany Levick: I am an employee of IQVIA

Eunji Nam: I have no conflict of interest to disclose

Dongkyu Kim: I have no conflict of interest to disclose

Roman Rouzier: I have no conflict of interest to disclose

Claire Bonneau: I have no conflict of interest to disclose

Paul Kubelac: served on a speaker’s bureau for Roche, Bristol-Myers Squibb, AstraZeneca, Novartis.

Patriciu Achimas-Cadariu: I have no conflict of interest to disclose

Jean-Marc Classe: I have no conflict of interest to disclose

François Bocquet: I have no conflict of interest to disclose

Sven Becker: I have no conflict of interest to disclose

Mariana Guergova-Kuras: I am an employee of IQVIA

Geoff Hall: I receive grant support and consultancy fees from IQVIA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.